重要内容提示： 1、根据《经修订和重述的和解和框架协议》约定，佰骏医疗应从 2025 年开始在每 个季度向公司偿还人民币不少于 600 万元，首次偿还日期为 2025 年 3 月 21 日。受春节 假期及其他因素影响，佰骏医疗在资金归集及调度工作上面临阶段性调整，本季度不能 按照《经修订和重述的和解和框架协议》约定的还款计划足额还款，其已于 2026 年 3 月 20 日偿还 300 万元借款，本季度剩余 300 万元还款预计将于 4 月底前偿还；在后续 还款过程中，如佰骏医疗按照相关协议规定时间节点向公司还款（含 4 月底前向公司还 款 300 万元），则公司将不再在相应时间节点进行进展公告； 2、风险提示：在佰骏医疗偿还完毕其所欠公司借款前，公司仍将面临佰骏医疗可 能因各种情况无法按时足额还款的风险，为保障公司权益不受损害，公司将持续密切关 注相关事项进展，并根据协议相关约定视情况追究其违约责任。请投资者注意相关风险， 谨慎投资。 一、佰骏医疗归还公司欠款进展 湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 证券代码：603998 证券简称：方盛制 ...

证券代码：603998 证券简称：方盛制药 公告编号：2026-015 湖南方盛制药股份有限公司 HUNANFANGSHENGPHARMACEUTICALCO.,LTD. 湖南方盛制药股份有限公司 关于司来帕格片获得《药品注册证书》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2026年3月20日，湖南方盛制药股份有限公司（以下简称"公 司"）收到国家药品监督管理局（以下简称"国家药监局"）核 准签发的《药品注册证书》，公司研发的司来帕格片已获得药品 批准文号，并可进行生产。现将相关情况公告如下： 二、药品的相关情况 司来帕格片由瑞士爱可泰隆（Actelion）原研，2015年12月 首次在美国获批上市，商品名为UPTRAVI，用于治疗肺动脉高 压（PAH，WHO第1组），以延缓疾病进展并降低因肺动脉高压 住院的风险。司来帕格片是一种口服有效、高选择性和长效的非 第 1页，共 3页 药品名称 司来帕格片 受理号 CYHS2403524 证书编号 2026S00780 主要成分 司来帕格 剂型 片剂 申请事项 药品注册 ...

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology industry [1]. Core Insights - The National People's Congress has designated innovative drugs as a "new emerging pillar industry," indicating a strategic shift for the biopharmaceutical sector from a nurturing phase to a core engine of economic growth [16][17]. - As of March 6, 2026, the total value of business development (BD) contracts for Chinese innovative drugs has reached $56.8 billion, with an upfront payment of $3.3 billion, representing 41% of the total for 2025 and exceeding the total for 2024 [17][21]. - Despite significant stock price corrections from 2025 highs, the fundamentals of quality companies remain solid, and the long-term growth logic for innovative drug exports is still intact [21]. Summary by Sections Industry Trends - The A-share pharmaceutical index has seen a year-to-date decline of 2.42%, underperforming the CSI 300 by 1.02% [9]. - The Hang Seng Healthcare Index has outperformed the Hang Seng Technology Index by 0.97% year-to-date [9]. R&D Progress and Company Dynamics - Recent approvals include HSK31679 for non-alcoholic fatty liver disease and the GLP-1 receptor agonist Enogratide, marking significant advancements in innovative drug development [17]. - The report highlights specific companies to watch, including: - PD1 PLUS: Sangamo Therapeutics, CanSino Biologics, Innovent Biologics, and Zai Lab [12]. - ADC: I-Mab Biopharma, Kelun-Biotech, and Baiyue Tianheng [12]. - Small nucleic acids: Frontier Biotechnologies, Fuyuan Pharmaceutical, and Yuyuan Pharmaceutical [12]. Market Performance - The report notes that the pharmaceutical index's price-to-earnings ratio is currently at 36.18, which is 2.24 times lower than the historical average [9]. - The report identifies top-performing stocks for the week, including Yahu Pharmaceutical (+40.65%) and Duoyi Pharmaceutical (+30.81%), while highlighting significant declines in stocks like Haixiang Pharmaceutical (-15.06%) and Furu Medical (-13.07%) [9].

湖南方盛制药股份有限公司 HUNANFANGSHENGPHARMACEUTICALCO.,LTD. 证券代码：603998 证券简称：方盛制药 公告编号：2026-014 湖南方盛制药股份有限公司 关于比索洛尔氨氯地平片获得《药品注册证书》的 公 告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2026年3月3日，湖南方盛制药股份有限公司（以下简称"公 司"）全资子公司广东方盛健盟药业有限公司（以下简称"健盟 药业"）收到国家药品监督管理局（以下简称"国家药监局"） 核准签发的《药品注册证书》，公司研发的比索洛尔氨氯地平片 已获得药品批准文号，并可进行生产。现将相关情况公告如下： 二、药品的相关情况 比索洛尔氨氯地平片由德国默克公司开发，于 2021 年 5 月 11 日在中国获批上市，批准规格为富马酸比索洛尔 5mg 与苯磺酸 第 1页，共 3页 药品名称 比索洛尔氨氯地平片 受理号 CYHS2403336 证书编号 2026S00527 主要成分 富马酸比索洛尔、苯磺酸氨氯地平 剂型 片剂 申请事项 药品注册（境内生产 ...

湖南方盛制药股份有限公司 HUNANFANGSHENGPHARMACEUTICALCO.,LTD. 证券代码：603998 证券简称：方盛制药 公告编号：2026-013 湖南方盛制药股份有限公司 关于产品中选集采药品协议期满品种接续采购的 公 告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2026 年 2 月 9 日，湖南方盛制药股份有限公司（以下简称 "公司"）参与了国家组织集采第 1-8 批协议期满品种接续采购 的申报，根据国家组织集采药品协议期满品种接续采购办公室 （以下简称"接续采购办公室"）于 2026 年 2 月 27 日发布的《关 于 公 布 国 家 组 织 集 采 药 品 协 议 期 满 品 种 接 续 采 购 （LC-YPJX-2026-1）中选结果的通知》，公司依折麦布片、头孢 克肟片、头孢丙烯片、厄贝沙坦氢氯噻嗪片、奥美拉唑肠溶片及 蒙脱石散中选本次接续采购。现将有关情况公告如下： 第 1页，共 3页 中选产品 适应症 规格 包装方式 依折麦布片 治疗原发性高胆固醇血症、纯合子家族性高胆固 醇血症 ...

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology sector [1] Core Insights - The upcoming adjustment of the National Essential Medicines List (NEML) is expected to benefit traditional Chinese medicine (TCM) stocks, with a focus on companies like Zhaoli Pharmaceutical, Fangsheng Pharmaceutical, and Panlong Pharmaceutical [2][17][22] - The report ranks sub-sectors in the following order of preference: innovative drugs > research services > CXO > TCM > medical devices > pharmacies [2][11] - Historical data indicates that products included in the NEML tend to experience significant sales growth, as seen with Zhaoli Pharmaceutical's Wuling Capsule, which saw sales growth rates increase from -12.82% in 2017 to 32.52% in 2021 after being included in the NEML [19][22] Summary by Sections Investment Highlights - The report suggests focusing on TCM stocks due to the imminent NEML adjustments, recommending Zhaoli Pharmaceutical, Fangsheng Pharmaceutical, and Panlong Pharmaceutical [2][17] - The report emphasizes the importance of the NEML adjustments, which have not occurred in eight years, and the potential for TCM products to gain market share [22] R&D Progress and Company Dynamics - Recent approvals and submissions include Sanofi's Dupilumab for new indications and GSK's hepatitis B therapy application in Japan [5] - The report highlights various companies across different therapeutic areas, including innovative drugs, ADCs, and small nucleic acids, suggesting a diversified investment approach [13][22] Market Performance - The A-share pharmaceutical index has shown a year-to-date increase of 3.0%, with notable performances from specific stocks such as Aidi Te (+36.9%) and Wanze Shares (+27.5%) [10] - The report notes that the medical sector has seen varied performance, with biopharmaceuticals and medical devices showing positive trends, while chemical pharmaceuticals and medical services have faced declines [10]

Core Viewpoint - The company is seeking feedback from investors, particularly small and medium-sized investors, regarding its profit distribution plan for the year 2025, aiming to enhance transparency and protect investor interests [1] Group 1: Profit Distribution Policy - The company's profit distribution policy emphasizes reasonable returns for investors and aims for continuity and stability in profit distribution [1] - According to the company's articles of association, if there are no significant investment plans or major cash expenditures, at least 15% of the distributable profits for the year should be distributed in cash [1] Group 2: Feedback Collection - The company will collect opinions on the 2025 profit distribution plan from March 1, 2026, to March 31, 2026, allowing investors to submit their feedback through various channels [1] - The profit distribution plan must be approved by the shareholders' meeting, and the board of directors is required to complete the dividend distribution within 60 days after the meeting [1]

Group 1 - The company is seeking investor opinions on the profit distribution plan for the fiscal year 2025 to enhance transparency and protect investor interests, especially for small and medium investors [1][2] - The profit distribution policy emphasizes reasonable returns for investors, maintaining continuity and stability, with a minimum cash dividend of 15% of the distributable profit if there are no major investment plans or cash expenditures [2] - The company will finalize the profit distribution plan based on shareholder meeting approvals, with a deadline for feedback from investors set from March 1, 2026, to March 31, 2026 [2]

湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 证券代码：603998 证券简称：方盛制药 公告编号：2026-012 《公司章程》第一百六十七条规定：公司的利润分配政策为： 公司的利润分配政策应重视对投资者的合理投资回报，利润分配 政策应保持连续性和稳定性；如无重大投资计划或重大现金支出 等事项发生，公司应当采取现金方式分配股利，以现金方式分配 的利润不少于当年实现的可分配利润的15%。（具体内容详见《公 司章程》第一百六十七条相关规定） 公司前三年的利润分配方案、资本公积金转增股本方案如下： | | | 湖南方盛制药股份有限公司 关于2025年度利润分配相关事项征求投资者意见的 公 告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据国务院办公厅《关于进一步加强资本市场中小投资者合 法权益保护工作的意见》、中国证券监督管理委员会《上市公司 监管指引第3号—上市公司现金分红》、上海证券交易所《上市 公司自律监管指引第1号—规范运作》以及《公司章程》的相关 规定和要 ...

Core Viewpoint - The announcement details the completion of share pledge releases by the controlling shareholder of Hunan Fangsheng Pharmaceutical Co., Ltd., Zhang Qinghua, indicating a significant reduction in pledged shares and a stable ownership structure [2][3]. Group 1: Share Pledge Release - Zhang Qinghua completed the release of 9.6252 million shares, which accounts for 2.19% of the company's total share capital [2]. - As of the announcement date, Zhang Qinghua directly holds 156,019,500 shares, representing 35.53% of the total shares (439,081,360 shares) [2]. - The total number of shares pledged by Zhang Qinghua is 54,450,000, which is 34.90% of his directly held shares and 12.40% of the company's total shares [2]. Group 2: Shareholding Structure - Zhang Qinghua, along with his concerted actions (Hunan Kaishun Investment Consulting Co., Ltd. and Zhang Zhurong), collectively holds 165,574,607 shares, with a total of 54,450,000 shares pledged, representing 32.89% of their total holdings [2]. - The subsidiary of Hunan Kaishun, Changsha Gongseng Investment Consulting Co., Ltd., holds 9,131,807 shares, with no shares pledged [2]. Group 3: Future Plans - There are currently no plans for further share pledge financing following the release of the pledged shares [3].